Precision Oncology in the Era of Health Care Reform Improving Outcomes, Sustaining Innovation, Increasing Efficiency

Companies and researchers are making exceptional progress in the battle against cancer. This paper makes the case for a new social contract for oncology drug development and reimbursement that can ensure that we accelerate the adoption of the right treatments to the right patients, while also experimenting with delivery-system reforms that may offer greater value to patients for every dollar spent on care.

• As access to high-quality oncology data and analytics improves, in real time and at the point of care, we have an opportunity to learn from every treatment decision and patient interaction so that we can improve outcomes and deliver better value across the entire cancer care ecosystem.
• Robust data-sharing of patient outcomes, combined with genomic and phenotypic data, can accelerate the advent of “precision oncology”—delivering the right treatment, at the right time, to the right patient; it can also serve as a platform for value-based reimbursement contracts that better align price with value by collecting data on critical metrics with much greater granularity.
• Regulatory reforms are needed to accelerate outcomes-based contracting, especially the creation of safe harbors from federal regulations governing “best price,” anti-kickback, and off-label prescribing.

READ FULL REPORT